Advanced GISTs including unresectable, recurrent or metastatic are initially managed by imatinib; however, GIST patients may have primary resistance to imatinib due to mutations in KIT or PDGFRA rendering the patients less responsive to imatinib. This evidence concerns the gene KIT and gastrointestinal stromal tumor.